http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
-
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
-
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
-
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Clearside Biomedical (CLSD) Submits NDA for XIPERE for Treatment of Macular Edema Associated with Uveitis
-
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
-
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
-
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
-
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
-
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
-
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
-
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
-
Clearside Biomedical (CLSD) Reports SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
-
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
-
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
-
Clearside Biomedical (CLSD) Highlights Additional Analysis of PEACHTREE Clinical Trial Data to Support Potential of XIPERE in Treating Uveitic
-
Presentation of Additional Analyses of Clearside’s PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE™ in Treating Uveitic Macular Edema
-
Presentation of Additional Analyses of Clearside’s PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE™ in Treating Uveitic Macular Edema
-
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
-
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
-
CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018
-
CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018
-
Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain
-
Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain
-
Clearside Biomedical (CLSD) Names Jeffrey Edwards to Board
-
Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors
-
Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors
-
Clearside Biomedical (CLSD) Announces Positive PEACHTREE Data to be Highlighted at EURETINA 2018
-
Positive PEACHTREE Data to be Highlighted at EURETINA 2018
-
Positive PEACHTREE Data to be Highlighted at EURETINA 2018
-
Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting
-
Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting
-
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
-
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
-
Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer
-
Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer
-
Clearside Biomedical to Participate in 2018 Janney Healthcare Conference
-
Clearside Biomedical to Participate in 2018 Janney Healthcare Conference
-
Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality
-
Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality
-
Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference
-
Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference
-
Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update
-
Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update
-
Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow
-
Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow
-
Clearside Biomedical to Present Data from its Pivotal Phase 3 (“PEACHTREE”) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting
-
Clearside Biomedical to Present Data from its Pivotal Phase 3 (“PEACHTREE”) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

